《Clinical risk assessment of biotin interference with a high-sensitivity cardiac troponin T assay》 was published in Clinical Chemistry and Laboratory Medicine in 2020. These research results belong to Mumma, Bryn; Diercks, Deborah; Twerenbold, Raphael; Valcour, Andre; Ziegler, Andre; Schuetzenmeister, Andre; Kasapic, Dusanka; Tran, Nam. Related Products of 58-85-5 The article mentions the following:
Objectives : Biotin >20.0 ng/mL (81.8 nmol/L) can reduce Elecsys Troponin T Gen 5 (TnT Gen 5; Roche Diagnostics) assay recovery, potentially leading to false-neg. results in patients with suspected acute myocardial infarction (AMI). We aimed to determine the prevalence of elevated biotin and AMI misclassification risk from biotin interference with the TnT Gen 5 assay. Methods : Biotin was measured using an Elecsys assay in two cohorts: (i) 797 0-h and 646 3-h samples from 850 US emergency department patients with suspected acute coronary syndrome (ACS); (ii) 2023 random samples from a US laboratory network, in which biotin distributions were extrapolated for higher values using pharmacokinetic modeling. Biotin >20.0 ng/mL (81.8 nmol/L) prevalence and biotin 99th percentile values were calculated AMI misclassification risk due to biotin interference with the TnT Gen 5 assay was modeled using different assay cutoffs and test timepoints. Results : ACS cohort: 1/797 (0.13%) 0-h and 1/646 (0.15%) 3-h samples had biotin >20.0 ng/mL (81.8 nmol/L); 99th percentile biotin was 2.62 ng/mL (10.7 nmol/L; 0-h) and 2.38 ng/mL (9.74 nmol/L; 3-h). Using conservative assumptions, the likelihood of false-neg. AMI prediction due to biotin interference was 0.026% (0-h result; 19 ng/L TnT Gen 5 assay cutoff). US laboratory cohort: 15/2023 (0.74%) samples had biotin >20.0 ng/mL (81.8 nmol/L); 99th percentile biotin was 16.6 ng/mL (68.0 nmol/L). Misclassification risk due to biotin interference (19 ng/L TnT Gen 5 assay cutoff) was 0.025% (0-h), 0.0064% (1-h), 0.00048% (3-h), and <0.00001% (6-h). Conclusions : Biotin interference has minimal impact on the TnT Gen 5 assay's clin. utility, and the likelihood of false-neg. AMI prediction is extremely low. In the experimental materials used by the author, we found 5-((3aS,4S,6aR)-2-Oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid(cas: 58-85-5Related Products of 58-85-5)
5-((3aS,4S,6aR)-2-Oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid(cas: 58-85-5) may be used to elute proteins from avidin/streptavidin resins. It has been used for culturing of oligodendrocytes.Related Products of 58-85-5 And it has been used for blocking endogenous biotin during immunohistology procedures.
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem